A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

NCT07089992 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: Pembrolizumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]